Brandão, Mariana http://orcid.org/0000-0002-1653-3544
Martins-Branco, Diogo http://orcid.org/0000-0002-7214-4818
De Angelis, Claudia http://orcid.org/0000-0003-0398-5610
Vuylsteke, Peter http://orcid.org/0000-0001-6401-3722
Gelber, Richard D. http://orcid.org/0000-0001-8270-8712
Van Damme, Nancy http://orcid.org/0000-0003-4636-7636
van Walle, Lien http://orcid.org/0000-0001-7356-8877
Ferreira, Arlindo R. http://orcid.org/0000-0002-1567-9322
Lambertini, Matteo http://orcid.org/0000-0003-1797-5296
Poggio, Francesca http://orcid.org/0000-0002-4518-2827
Verhoeven, Didier http://orcid.org/0000-0002-7748-0837
Barbeaux, Annelore http://orcid.org/0000-0003-4003-0864
Duhoux, Francois P. http://orcid.org/0000-0002-5429-7888
Wildiers, Hans http://orcid.org/0000-0001-8990-7837
Caballero, Carmela http://orcid.org/0000-0002-3586-6598
Awada, Ahmad http://orcid.org/0000-0001-7412-9163
Piccart-Gebhart, Martine http://orcid.org/0000-0001-9068-8504
Punie, Kevin http://orcid.org/0000-0002-1162-7963
de Azambuja, Evandro http://orcid.org/0000-0001-9501-4509
Funding for this research was provided by:
Belgian Society of Medical Oncology (N/A)
Fonds Pink Ribbon (N/A)
Article History
Received: 22 June 2023
Accepted: 24 August 2023
First Online: 25 October 2023
Change Date: 9 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s10549-024-07275-0
Declarations
:
: Research grants to Institut Jules Bordet (MB, DMB, CDA, AA, MP, EdA): from Roche/GNE, Radius, AstraZeneca, Lilly, MSD, GSJ/Novartis, Synthon, Servier, and Pfizer (all outside the submitted work). MB: travel grant from Roche, Takeda and Sanofi; speaker honoraria from Roche, Takeda and Janssen; advisory board from Sanofi (all outside the submitted work). DMB: honoraria from Daiichi Sankyo, Novartis, Merck Sharp & Dohme, Janssen, Pfizer, and Angelini; Meeting/travel grants from Novartis, Merck Sharp & Dohme, LEO Farmacêuticos, Ipsen, Janssen; (all outside the submitted work). PV: travel, speakers and advisory fees via Roche, MSD, BMS, Pfizer, Novartis, Lilly. ARF: honoraria and/or advisory board fees from Daiichi Sankyo, Gilead, Merck Sharp & Dohme, Novartis, Roche; meeting/travel grants: Roche (all outside the submitted work). ML: consultancy for Roche, Lilly, AstraZeneca, Pfizer, Novartis, MSD, Seagen, Exact Sciences, Gilead; speaker honoraria from Roche, Takeda, Ipsen, Sandoz, Knight, Libbs, Lilly, Pfizer, Novartis, Daiichi Sankyo, Gilead; travel grant from Gilead; institutional research grant from Gilead. FP: support for attending meetings from Daichii Sankyo and Gilead; participation on advisory board from AstraZeneca; and fees or honoraria from Eli Lilly and Novartis (all outside the submitted work). FPD: advisory role (support to Institution) for Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, Gilead, Mundipharma, Novartis, Pfizer, Pierre Fabre, Roche, Seagen, and Teva. HW: his institution received financial compensation on his behalf for advisory boards, lecture fees and/or consultancy fees from Immutep Pty, MSD, Astrazenca, Daiichi, AbbVie, Lilly, Roche, EISAI, Pfizer, Sirtex, Gilead; travel grant from Pfizer and Roche. CC: employment at Breast International Group; institution research grant from AstraZeneca, Roche/Genentech, Tesaro, Novartis, Pfizer, SERVIER, Biovica, GlaxoSmithKline, and Sanofi/Aventis; institutional royalties from Agendia for MammaPrint; board member of European Society of Surgical Oncology (all outside of submitted work). AA: advisory role, research grants to my Institute, speaker fees: Roche, Lilly, Amgen, EISAI, BMS, Pfizer, Novartis, MSD, Genomic Health, Ipsen, AstraZeneca, Bayer, Leo Pharma. MPG: consultancy for AstraZeneca, Lilly, MSD, Novartis, Odonate, Pfizer, Roche, Camel-IDS, Crescendo Biologics, Periphagen, Huya, Debiopharm, PharmaMar, G1 Therapeutics, Menarini, Seattle Genetics, Immunomedics, and Oncoloytics; board member of Radius. KP: research grants to institute from MSD and Sanofi; speaker fees and honoraria for consultancy and advisory board functions from Astra Zeneca, Eli Lilly, Exact Sciences, Focus Patient, Gilead, MSD, Novartis, Pfizer, Roche, and Seagen; speaker fees and honoraria for consultancy and advisory board functions to institution from Astra Zeneca, Eli Lilly, Exact Sciences, Gilead, MSD, Novartis, Pfizer, Roche, and Seagen; stock options from Need Inc; travel grants from Astra Zeneca, Novartis, Pfizer, PharmaMar, and Roche. EdA: Honoraria and advisory board from Roche/GNE, Novartis and SeaGen. Travel grants from Roche/GNE and GSK/Novartis. Other authors: no conflicts of interest.
: Approval of the Ethical committee was not necessary based on the fact that this retrospective study does not fall under the Belgian Law of 7 May 2004 regarding experiments on human persons (art. 3,§ 2).